Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Subacromial Impingement, Subacromial Impingement Syndrome
Interventions: Ketorolac Tromethamine, Methylprednisolone Acetate; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Abstinence-only HIV/STD risk-reduction intervention, Safer-sex-only HIV/STD risk-reduction intervention, Long comprehensive HIV/STD risk-reduction intervention, Short comprehensive HIV/STD risk-reduction intervention, Health promotion control intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 662 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Interventions: Echography-guided Surfactant THERapy (ESTHER); Diagnostic Test
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Septic Shock
Interventions: Plasma, Balanced crystalloids; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Short Bowel Syndrome
Interventions: recombinant human growth hormone, diet modification; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Persistent Pulmonary Hypertension of Newborn
Interventions: Not listed
Lead sponsor: Christiana Care Health Services; Other
Eligibility: Up to 6 Months
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Newark, Delaware • Philadelphia, Pennsylvania

Conditions: Plantar Fasciitis, Achilles Tendinitis, Patellofemoral Pain Syndrome
Interventions: Spinal and Peripheral Dry Needling, Peripheral Dry Needling; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Severe Acute Respiratory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye, Visual Acuity
Interventions: Preservative Free eye drop; Drug
Lead sponsor: Southern College of Optometry; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 4
States / cities: Orlando, Florida • Medina, Minnesota • Warwick, Rhode Island + 1 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: oral glucose tolerance test, MRI of liver; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: PML, AIDS
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 5 more

Conditions: Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
Interventions: Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy; Diagnostic Test · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 34 Years to 34 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Infections
Interventions: Pegylated interferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Durham, North Carolina

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Houston, Texas

Conditions: Influenza and Other Novel Respiratory Viruses
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 11,719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more

Conditions: Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: Up to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Clinical High Risk for Psychosis
Interventions: Targeted Cognitive Training, Computer Games; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 15 Years to 30 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Tourette Syndrome
Interventions: Gemlapodect, Placebo; Drug
Lead sponsor: Noema Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 31
States / cities: Sun City, Arizona • Bellflower, California • Glendale, California + 28 more

Conditions: Insulin Resistance, Hypertriglyceridemia
Interventions: Rosiglitazone, Fenofibrate, Weight Loss; Drug · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma
Interventions: educational intervention, informational intervention, internet-based intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration, psychosocial assessment and care, quality-of-life assessment, standard follow-up care; Other · Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 2 Months to 18 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Search by objective public record fields.

Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement

Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock

Diet/Growth Factor Mechanisms of Gut Adaptation

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only

Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)

Treating Lid Wiper Epitheliopathy

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Post-Prandial Liver Glucose Metabolism in PCOS

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

ATHENA: Natural History of Disease Study in Alport Syndrome Patients

A Case Report of NMDAR Encephalopathy

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

Respiratory Virus Outpatient Study (FLU 002 Plus)

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families